Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Joan T. Garrett; Anindita Chakrabarty; Carlos L. Arteaga

doi:10.18632/oncotarget.26017

Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Joan T. Garrett, Anindita Chakrabarty, Carlos L. Arteaga

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

Original language	English (US)
Pages (from-to)	32400
Number of pages	1
Journal	Oncotarget
Volume	9
Issue number	64
DOIs	https://doi.org/10.18632/oncotarget.26017
State	Published - Aug 17 2018
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.26017

Cite this

@article{0bfb2092e4324f348381704874930af4,

title = "Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409",

abstract = "This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.",

author = "Garrett, {Joan T.} and Anindita Chakrabarty and Arteaga, {Carlos L.}",

note = "Publisher Copyright: {\textcopyright} 2018, Garrett et al.",

year = "2018",

month = aug,

day = "17",

doi = "10.18632/oncotarget.26017",

language = "English (US)",

volume = "9",

pages = "32400",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "64",

}

TY - JOUR

T1 - Correction

T2 - Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

AU - Garrett, Joan T.

AU - Chakrabarty, Anindita

AU - Arteaga, Carlos L.

PY - 2018/8/17

Y1 - 2018/8/17

N2 - This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

AB - This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

UR - http://www.scopus.com/inward/record.url?scp=85051769625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051769625&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26017

DO - 10.18632/oncotarget.26017

M3 - Comment/debate

C2 - 30190795

AN - SCOPUS:85051769625

SN - 1949-2553

VL - 9

SP - 32400

JO - Oncotarget

JF - Oncotarget

IS - 64

ER -

Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this